Vaccine protection against SIVmac239 acquisition

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Developing a preventive vaccine for human immunodeficiency virus (HIV) is challenging due to the complex biological characteristics of the virus.
• Existing vaccine strategies have struggled to induce protective immunity against simian-immunodeficiency-virus (SIV) in non-human primate models, particularly against the difficult-to-neutralize SIVmac239 strain.

Purpose of the Study:

• To evaluate the efficacy of a novel vaccine regimen in providing significant protection against SIVmac239 acquisition.
• To assess the durability of immune responses elicited by the engineered herpesvirus vaccine.

Main Methods:

• A replication-competent herpesvirus was engineered to carry a near-full-length simian-immunodeficiency-virus (SIV) genome, expressing all nine SIV gene products.
• The engineered virus was used to vaccinate rhesus monkeys, inducing long-lasting effector-memory cellular immune responses.
• Vaccinated monkeys were challenged intravenously with SIVmac239 over a 4-month period to assess protection against acquisition.

Main Results:

• Vaccinated rhesus monkeys demonstrated significant protection against intravenous acquisition of SIVmac239.
• The protection was observed following repeated low-dose challenges over an extended period.
• The vaccine regimen successfully elicited immune responses to all nine SIV gene products.

Conclusions:

• The engineered herpesvirus vaccine provides a promising long-lasting approach for achieving significant protection against SIV acquisition.
• Further research is required to identify key components for protective immunity, assess protection against diverse SIV strains, and explore human applicability.